Can Duvakitug Redefine IBD Therapy?Teva Pharmaceuticals, in a groundbreaking collaboration with Sanofi, has unveiled results from the Phase 2b RELIEVE UCCD study that could potentially reshape the landscape of inflammatory bowel disease (IBD) treatment. The study's focus, duvakitug, a novel anti-TL1A monoclonal antibody, has shown re
